Leukemia and NK CAR Scientist in @lab_rezvani at MD Anderson Cancer Center & a proud aiimsonian.
Houston,Texas
Joined July 2017
- Tweets53
- Following67
- Followers36
- Likes64
Bijender Kumar retweeted
Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical demonstration of NK cell redirection using a bispecific engager. We report an ORR of 92.9% and CR of 66.7% in 42 patients with a median of 7 prior therapies and show that this approach is safe and may serve as a bridge to SCT. Excited to move forward with our next generation engineered NK cells in combination with engagers and mAbs. #CancerResearch #Immunotherapy #NKcells @MDAndersonNews
Findings from a Phase I trial suggest natural killer cells pre-complexed with AFM13 has promise for specific patients with lymphoma and may be adapted for more cancer types in the future.
Learn more: brnw.ch/21wRN45 #EndCancer
Bijender Kumar retweeted
This will be an amazing symposium for those interested in myeloid malignancies. Checkout the exciting program organized by @CollaSimona ! I will be presenting some of our work on NK cell epigenetic scarring in MDS and AML. @MDAndersonNews #MDS #AML #NK
Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. @CollaSimona at @MDAndersonNews in May 2025!
The speaker line up is phenomenal & the science is cutting edge.
Register 👇🏼 join us & RT pls
mdanderson.cloud-cme.com/cou…
#MDSsm
Bijender Kumar retweeted
Thank you, Dr. Pisters for your inspiring vision. Our team of dedicated scientists and clinicians is committed to advancing cell therapies that will bring transformative treatments to patients with cancer, autoimmune disorders and infection diseases @MDAndersonNews #CellTherapy #endcancer
Today, @MDAndersonNews launched the Institute for Cell Therapy Discovery & Innovation, which aims to lead the world in developing and advancing cell therapies for patients in need. By uniting top scientists and clinicians, we look forward to uncovering new insights in immunology and cell engineering, fueling the creation of transformational new treatments for cancer, autoimmune diseases, infections and other conditions.
ALT Katy Rezvani speaks
ALT Four speakers sit in chairs
ALT Wide crowd shot of institute launch event
ALT Portrait of patient JC Cox
Bijender Kumar retweeted
Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF
Bijender Kumar retweeted
The future of cell therapy! CAR NK! @MDAndersonNews
Many congratulations to our Dr. Sunil Acharya @sunilacharya13 for his exciting research on CD70-targeting CAR NK cells, published in Cancer Discovery! Sunil and his co-authors showed that the incorporation of CD28 costimulation, which is normally absent in NK cells, in the CAR construct improves efficacy of CAR NK cells via the LCK/CD3ζ/ZAP70 pathway. Sincere thanks to our collaborators for their invaluable contributions. We’re excited about the promising clinical trials ahead! @MDAndersonNews #CancerResearch #Immunotherapy #CAR_NKCells @kchenken @UH_NVLab
Bijender Kumar retweeted
Tour de force presentation today by Dr. Katy Rezvani @lab_rezvani at the Allison Institute @MDAndersonNews encompassing great science and a proliferative pipeline of cell therapies for our patients with heme and solid cancers! #NK #celltherapy
Bijender Kumar retweeted
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents dlvr.it/T393jD
Bijender Kumar retweeted
Our Dr. Katy Rezvani, recipient of @ASH_hematology’s 2023 Honorific Award, delivers the E. Donnall Thomas Lecture at #ASH23 on Natural Killer Cells: A New Frontier for Cancer Immunotherapy.
We’re grateful for her pioneering contributions to this innovative field and her commitment to #EndCancer. @lab_rezvani
ALT Dr. Katy Rezvani delivers the E. Donnall Thomas Lecture at ASH23
Bijender Kumar retweeted
Thank you very much Dr. Brodsky @DocsDock200 for your very kind words! It was such an honor to receive this award from ASH. Please accept my sincere congratulations for presiding over such an amazing #ASH23 @MDAndersonNews
Bijender Kumar retweeted
Stunning and brilliant! A stellar lecture by @lab_rezvani to showcase the groundbreaking research and very promising clinical responses in patients treated with #CARNK cells. Katy -may your star keep shining as we carry on our mission to make cancer history @MDAndersonNews #ASH – at San Diego, CA
Bijender Kumar retweeted
In an #ASH23 Scientific Spotlight Session, our Dr. May Daher shares insights on metabolic targets and strategies to enhance the efficacy of cellular therapies, such as CAR NK. @ASH_hematology @may_daher #EndCancer
Outstanding presentations by @may_daher & @Byersdoc_BMT at the Immunometabolism as a tool to advance cell therapy session #ASH23 describing novel strategies to modulate and enhance the potency of immune effector cells for adoptive therapy @MDAndersonNews
Bijender Kumar retweeted
‘The mind is not a vessel to be filled, but a fire to be kindled.’ - Plutarch. Medical training, especially at esteemed institutions like AIIMS, is about igniting this fire, focusing on practical skills and immersive learning, rather than just traditional grading. The hours listed represent a journey of hands-on dedication and in-depth understanding, crucial for the medical profession.
@SeeFisch; You must visit to see the magic of @aiims_newdelhi :) – at Pearland, TX
This quoted post is unavailable.
Bijender Kumar retweeted
“I work within a field that could potentially result in a cure for at least a subset of patients with cancer,” says our Dr. Katy Rezvani of cellular therapy.
Learn how working at MD Anderson has shaped Rezvani’s career and her research: bit.ly/3LOUxtF @GoHealio @lab_rezvani #EndCancer
Bijender Kumar retweeted
An amazing presentation by @may_daher at this afternoon’s @SNI_NKMeeting session on her research in the impact of AML on NK cells. So very proud of all that she is doing to give hope to our patients #NK #NKCAR #NK2023 @MDAndersonNews
Bijender Kumar retweeted
Wonderful to celebrate such impressive scientific progress @EBMT2023 @lab_rezvani
#NKcells for CAR therapy 👏👏
So many more exciting Rx options for our patients since our training together #HammersmithHospital ‘some years’ ago with fabulous John Goldman @charliecraddock
Bijender Kumar retweeted
Awe-inspiring talk by Dr. Katy Rezvani @lab_rezvani @MDAndersonNews #EBMT2023! Impressive pipeline of NK cell based immunotherapies for multiple heme and solid cancers!! And this incredible response👇🏻 with CD70- directed CAR-NK cells!!! The future is bright!! 🤩
Bijender Kumar retweeted
When your mentor is a celebrity 😎 @lab_rezvani – at Houston, TX
.@Lab_Rezvani's inspiring vision to #EndCancer, rooted in childhood, drove her journey to discovery. Her CAR NK program @MDAndersonNews has opened up an entirely new approach to cellular therapy. Thrilled to see her recognized by @Endpts as a trailblazing woman in biopharma.
Bijender Kumar retweeted
@lab_rezvani @MDAndersonNews gives a masterclass in #NK Immunotherapy #SITC22. A must for all. @sitcancer 2022.sitc.showcare.io/lesson…
Bijender Kumar retweeted
Very excited to show this video that depicts macrophage - stem cell interactions. Someday, we hope to alter this interaction to remove pre malignant or leukemic clones of stem cells.
In recent @ScienceMagazine, @SamWattrus @leonard_zon + al in @BCHStemCell show #macrophages in #zebrafish embryos ensure quality of #hematopoietic #stemcells by “grooming” or “dooming” them
Paper bit.ly/abo4837
Bijender Kumar retweeted
Outstanding research paper coming out of our lab in @NatureMedicine with the leadership of @lab_rezvani! Congratulations Ethan and Katy! Great progress in the field! @MDAndersonNews
A new dual-chimeric antigen receptor (CAR) system enhances the antitumor activity of CAR natural killer cells and makes them less susceptible to therapeutic #resistance in preclinical models. @lab_rezvani
#CARNK #therapyresistance
nature.com/articles/s41591-0…
